Edgar Filing: PDL BIOPHARMA, INC. - Form 4

PDL BIOPH	ARMA, INC.										
Form 4											
July 08, 2015	5										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB AF	OMB APPROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check this box									Expires:	January 31	
if no longer subject to STATEMENT OF CHAN				GES IN BENEFICIAL OW				NERSHIP OF	Estimated a	2005 Werage	
Section 1	6.			SECURITIES					burden hours per		
Form 4 or					~	-		response 0.5			
Form 5 obligatior	•						•	e Act of 1934,			
may conti				•	U			f 1935 or Section	n		
<i>See</i> Instru 1(b).	iction	30(n)	of the In	vestment	Company	Act	01 194	Ю			
(Print or Type R	Responses)										
Pietzke Steffen Symbol				Issuer Name and Ticker or Trading bol				5. Relationship of Reporting Person(s) to Issuer			
				OPHARM	IA, INC.	[PD]	LI]	(Chas	1 11 1: 1. 1.	`	
(Last)	(First) (Middle)	3. Date of	Earliest Tra	ansaction			(Cnec	k all applicable	;)	
				th/Day/Year)				Director 10% Owner			
932 SOUTH	07/06/2015					_X_ Officer (give title Other (specify below) below) Controller and CAO					
				nendment, Date Original				6. Individual or Joint/Group Filing(Check			
				Aonth/Day/Year)				Applicable Line)			
INCLINE V	ILLAGE, NV 89	0451						_X_ Form filed by C Form filed by M	One Reporting Pe fore than One Re		
INCLINE V	ILLAUL, INV 05	9431						Person			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecuri	ties Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)		n Date, if	3. Transactio Code (Instr. 8)	4. Securiti n(A) or Dis (Instr. 3, 4	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
						or		Transaction(s) (Instr. 3 and 4)			
C				Code V	Amount	(D)	Price	(insur 5 und 1)			
Common stock	07/06/2015			А	14,748 (1)	А	\$ 6.18	14,748	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	4. Transac Code (Instr. 8	5. tionNumber of) Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	5	Date	Under Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
		Code Y	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: PDL BIOPHARMA, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Pietzke Steffen 932 SOUTHWOOD BLVD. INCLINE VILLAGE, NV 89451			Controller and CAO					
Signatures								
/s/ Nathan N. Kryszak, Attorney-in- Pietzke	effen	07/07/2015						
<u>**</u> Signature of Reporting Pe	rson		Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved,

based upon the following schedule: 50% on December 2016; 16.66% on December 2017; 16.66% on December 2018; and 16.66% on December 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.